95 related articles for article (PubMed ID: 23432722)
21. Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
Goyal S; Oak E; Luo J; Cashen AF; Carson K; Fehniger T; DiPersio J; Bartlett NL; Wagner-Johnston ND
Leuk Lymphoma; 2018 Feb; 59(2):357-362. PubMed ID: 28597723
[TBL] [Abstract][Full Text] [Related]
22. Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission.
Wu JJ; Guitart J; Tucker RM; Kuzel TM; Rosen ST
Int J Dermatol; 2003 Jun; 42(6):464-5. PubMed ID: 12786875
[No Abstract] [Full Text] [Related]
23. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ
Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676
[TBL] [Abstract][Full Text] [Related]
24. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
[No Abstract] [Full Text] [Related]
25. Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
Wu L; Wang J; Li Y; Zuo L; Zhang Z; Ouyang J; Fan J; Li H
Anticancer Drugs; 2014 Aug; 25(7):826-31. PubMed ID: 24423982
[TBL] [Abstract][Full Text] [Related]
26. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
Hematol Oncol; 2024 Jan; 42(1):e3247. PubMed ID: 38287530
[No Abstract] [Full Text] [Related]
27. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
Hematol Oncol; 2024 Jan; 42(1):e3242. PubMed ID: 38126215
[No Abstract] [Full Text] [Related]
28. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Petersen GH; Alzghari SK; Chee W; Sankari SS; La-Beck NM
J Control Release; 2016 Jun; 232():255-64. PubMed ID: 27108612
[TBL] [Abstract][Full Text] [Related]
29. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Cascinu S; Galizia E; Labianca R; Ferraù F; Pucci F; Silva RR; Luppi G; Beretta GD; Berardi R; Scartozzi M
Cancer Chemother Pharmacol; 2011 Jul; 68(1):37-43. PubMed ID: 20821330
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
31. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
32. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation.
Clozel T; Deau B; Benet C; Franchi P; Robin M; Madelaine I; Thieblemont C; de Kerviler E; Brière J; Brice P
Br J Haematol; 2013 Sep; 162(6):846-8. PubMed ID: 23789905
[No Abstract] [Full Text] [Related]
33. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
34. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
36. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A; Hatzidarellis EP; Alamara C; Dilana K; Pantazopoulos K; Kotteas E; Georgatou N; Syrigos KN
In Vivo; 2006; 20(4):553-7. PubMed ID: 16900789
[TBL] [Abstract][Full Text] [Related]
37. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
Hau P; Fabel K; Baumgart U; Rümmele P; Grauer O; Bock A; Dietmaier C; Dietmaier W; Dietrich J; Dudel C; Hübner F; Jauch T; Drechsel E; Kleiter I; Wismeth C; Zellner A; Brawanski A; Steinbrecher A; Marienhagen J; Bogdahn U
Cancer; 2004 Mar; 100(6):1199-207. PubMed ID: 15022287
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Li ZH; Xing MT; Zhang YP; Wang Y; Zhan XR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):744-8. PubMed ID: 27342502
[TBL] [Abstract][Full Text] [Related]
39. Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome.
Alaoua A; Gilbert G; Ghannouchi N; Houchlef M; Letaief A; Bahri F
Ann Endocrinol (Paris); 2011 Jun; 72(3):247-50. PubMed ID: 21640976
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
